Faeth Therapeutics (FTH) Prepaid Assets (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Prepaid Assets came in at $1.4 million in Q2 2026, up 64.13% on a YoY basis from $828000.0 in Q2 2025, and up 39.53% quarter-over-quarter from $974000.0 in Q1 2026.
Analysis
Faeth Therapeutics (FTH) Prepaid Assets (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has reported Prepaid Assets for 7 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets rose 64.13% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (up 64.13% YoY), and the FY2025 full-year result was $231000.0, down 51.27% from the prior year.
- Prepaid Assets rose to $1.4 million in Q2 2026 per FTH's latest filing, from $974000.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $3.5 million in Q2 2022 and bottomed at $231000.0 in Q4 2025.
- Historically, Prepaid Assets has averaged $1.4 million across 5 years, with a median of $1.3 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets soared 106.4% in 2022, then slumped 59.42% in 2024.
- Over 5 years, Prepaid Assets stood at $1.1 million in 2022, then increased by 3.45% to $1.2 million in 2023, then plunged by 59.42% to $474000.0 in 2024, then tumbled by 51.27% to $231000.0 in 2025, then surged by 488.31% to $1.4 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.4 million, $974000.0, and $231000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Faeth Therapeutics | 218.99 Mn | 218.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Mn |
| Mar 31, 2026 | 974,000.00 |
| Dec 31, 2025 | 231,000.00 |
| Sep 30, 2025 | 496,000.00 |
| Jun 30, 2025 | 828,000.00 |
| Mar 31, 2025 | 911,000.00 |
| Dec 31, 2024 | 474,000.00 |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.88 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Sep 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 1.98 Mn |
| Mar 31, 2023 | 2.65 Mn |
| Dec 31, 2022 | 1.13 Mn |
| Sep 30, 2022 | 1.59 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Mar 31, 2022 | 2.55 Mn |
| Dec 31, 2021 | 547,000.00 |
| Sep 30, 2021 | 1.20 Mn |